Examination of the current top candidate genes for AD in a genome-wide association study

Molecular Psychiatry

Volumn 15, Issue 7, 2010, Pages 756-766

  Feulner, T M ^a   Laws, S M ^a,b   Friedrich, P ^a   Wagenpfeil, S ^a   Wurst, S H R ^a   Riehle, C ^a   Kuhn, K A ^a   Krawczak, M ^c   Schreiber, S ^c   Nikolaus, S ^c   Forstl H ^a   Kurz, A ^a   Riemenschneider, M ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b EDITH COWAN UNIVERSITY   (Australia)

^c UNIVERSITY OF KIEL   (Germany)

^d SAARLAND UNIVERSITY   (Germany)

Author keywords

AlzGene; Alzheimer disease; candidate genes; genetics; genome wide association study

Indexed keywords

APOLIPOPROTEIN E;

AGED; ALZHEIMER DISEASE; ARTICLE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GERMANY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS; COMPARATIVE STUDY; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; PROCEDURES;

AGED; ALZHEIMER DISEASE; DATABASES, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77953912200     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2008.141     Document Type: Article

References (52)

1. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991; 349: 704-706. (Pubitemid 21912142)
2. Levy-Lahad E, Lahad A, Wijsman EM, Bird TD, Schellenberg GD. Apolipoprotein E genotypes and age of onset in early-onset familial Alzheimer's disease. Ann Neurol 1995; 38: 678-680.
3. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995; 375: 754-760.
4. Saunders AM. Gene identification in Alzheimer's disease. Phar-macogenomics 2001; 2: 239-249.
5. Sando SB, Melquist S, Cannon A, Hutton ML, Sletvold O, Saltvedt I et al. APOE epsilon4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol 2008; 8: 9.
6. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261: 921-923.
7. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell Jr PC et al. Protective effect of apolipo-protein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994; 7: 180-184.
8. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993; 90: 8098-8102.
9. McDowell I. Alzheimer's disease: insights from epidemiology. Aging (Milano) 2001; 13: 143-162.
10. Daw EW, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD et al. The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 2000; 66: 196-204.
11. Bertram L, Blacker D, Mullin K, Keeney D, Jones J, Basu S et al. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science 2000; 290: 2302-2303.
12. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D et al. Susceptibility locus for Alzheimer's disease on chromosome 10. Science 2000; 290: 2304-2305.
13. Myers A, Wavrant De-Vrieze F, Holmans P, Hamshere M, Crook R, Compton D et al. Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet 2002; 114: 235-244.
14. Li YJ, Scott WK, Hedges DJ, Zhang F, Gaskell PC, Nance MA et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet 2002; 70: 985-993.
15. Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Baker M, Adamson J et al. Linkage of plasma Abeta42 to a quantitative locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. Science 2000; 290: 2303-2304.
16. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-1356.
17. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17-23.
18. Martin ER, Lai EH, Gilbert JR, Rogala AR, Afshari AJ, Riley J et al. SNPing away at complex diseases: analysis of single-nucleotide polymorphisms around APOE in Alzheimer disease. Am J Hum Genet 2000; 67: 383-394.
19. Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E et al. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: patterns of linkage disequilibrium and disease/marker association. Genomics 2007; 89: 655-665.
20. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008; 65: 45-53.
21. Reiman EM, Webster JA, Myers AJ, Hardy J, Dunckley T, Zismann VL et al. GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron 2007; 54: 713-720.
22. Grupe A, Abraham R, Li Y, Rowland C, Hollingworth P, Morgan A et al. Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet 2007; 16: 865-873.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
24. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, Verma S et al. CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 1986; 149: 698-709.
25. Welsh KA, Butters N, Mohs RC, Beekly D, Edland S, Fillenbaum G et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsycho-logical battery. Neurology 1994; 44: 609-614.
26. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
27. Gunderson KL, Steemers FJ, Lee G, Mendoza LG, Chee MS. A genome-wide scalable SNP genotyping assay using microarray technology. Nat Genet 2005; 37: 549-554.
28. Steemers FJ, Chang W, Lee G, Barker DL, Shen R, Gunderson KL. Whole-genome genotyping with the single-base extension assay. Nat Methods 2006; 3: 31-33.
29. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-1320.
30. Conrad DF, Andrews TD, Carter NP, Hurles ME, Pritchard JK. A high-resolution survey of deletion polymorphism in the human genome. Nat Genet 2006; 38: 75-81.
31. Hinds DA, Kloek AP, Jen M, Chen X, Frazer KA. Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet 2006; 38: 82-85.
32. McCarroll SA, Hadnott TN, Perry GH, Sabeti PC, Zody MC, Barrett JC et al. Common deletion polymorphisms in the human genome. Nat Genet 2006; 38: 86-92.
33. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B et al. The structure of haplotype blocks in the human genome. Science 2002; 296: 2225-2229.
34. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265.
35. Cook LJ, Ho LW, Taylor AE, Brayne C, Evans JG, Xuereb J et al. Candidate gene association studies of the alpha 4 (CHRNA4) and beta 2 (CHRNB2) neuronal nicotinic acetylcholine receptor subunit genes in Alzheimer's disease. Neurosci Lett 2004; 358: 142-146.
36. Papassotiropoulos A, Lambert JC, Wavrant-De Vrieze F, Wollmer MA, von der Kammer H, Streffer JR et al. Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Neurodegener Dis 2005; 2: 233-241.
37. Finckh U, von der Kammer H, Velden J, Michel T, Andresen B, Deng A et al. Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol 2000; 57: 1579-1583.
38. Dodel RC, Du Y, Depboylu C, Kurz A, Eastwood B, Farlow M et al. A polymorphism in the cystatin C promoter region is not associated with an increased risk of AD. Neurology 2002; 58: 664.
39. Cathcart HM, Huang R, Lanham IS, Corder EH, Poduslo SE. Cystatin C as a risk factor for Alzheimer disease. Neurology 2005; 64: 755-757.
40. Mukherjee O, Kauwe JS, Mayo K, Morris JC, Goate AM. Haplotype-based association analysis of the MAPT locus in late onset Alzheimer's disease. BMC Genet 2007; 8: 3.
41. Myers AJ, Pittman AM, Zhao AS, Rohrer K, Kaleem M, Marlowe L et al. The MAPT H1c risk haplotype is associated with increased expression of tau and especially of 4 repeat containing transcripts. Neurobiol Dis 2007; 25: 561-570.
42. Laws SM, Friedrich P, Diehl-Schmid J, Muller J, Eisele T, Bauml J et al. Fine mapping of the MAPT locus using quantitative trait analysis identifies possible causal variants in Alzheimer's disease. Mol Psychiatry 2007; 12: 510-517.
43. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, Zou F et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat Genet 2007; 39: 168-177.
44. Lee JH, Cheng R, Schupf N, Manly J, Lantigua R, Stern Y et al. The association between genetic variants in SORL1 and Alzheimer disease in an urban, multiethnic, community-based cohort. Arch Neurol 2007; 64: 501-506.
45. Myers AJ, Kaleem M, Marlowe L, Pittman AM, Lees AJ, Fung HC et al. The H1c haplotype at the MAPT locus is associated with Alzheimer's disease. Hum Mol Genet 2005; 14: 2399-2404.
46. Bettens K, Brouwers N, Engelborghs S, De Deyn PP, Van Broeckhoven C, Sleegers K. SORL1 is genetically associated with increased risk for late-onset Alzheimer disease in the Belgian population. Hum Mutat 2008; 29: 769-770.
47. Kolsch H, Jessen F, Wiltfang J, Lewczuk P, Dichgans M, Kornhuber J et al. Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci Lett 2008; 440: 68-71.
48. Lee JH, Cheng R, Honig LS, Vonsattel JP, Clark L, Mayeux R. Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. Neurology 2008; 70: 887-889.
49. Riemenschneider M, Mahmoodzadeh S, Eisele T, Klopp N, Schwarz S, Wagenpfeil S et al. Association analysis of genes involved in cholesterol metabolism located within the linkage region on chromosome 10 and Alzheimer's disease. Neurobiol Aging 2004; 25: 1305-1308.
50. Cao H, van der Veer E, Ban MR, Hanley AJ, Zinman B, Harris SB et al. Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 898-903.
51. Arvanitakis Z, Wilson RS, Bennett DA. Diabetes mellitus, dementia, and cognitive function in older persons. J Nutr Health Aging 2006; 10: 287-291.
52. Wollstein A, Herrmann A, Wittig M, Nothnagel M, Franke A, Nurnberg P et al. Efficacy assessment of SNP sets for genome-wide disease association studies. Nucleic Acids Res 2007; 35: e113.